A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
Status:
Terminated
Trial end date:
2019-09-18
Target enrollment:
Participant gender:
Summary
This study evaluates whether it is safe to administer a peptide vaccine with ipilimumab. This
study will also evaluate the effects of the combination of the peptide vaccine and ipilimumab
on the immune system. The investigators will monitor these effects by performing tests in the
laboratory on participants' blood, a lymph node, and tumor samples.